AV-Comparatives Announces Outstanding Results of Cybersecurity Solutions in 2024 Endpoint Prevention and Response (EPR) Test
Download the full report here. INNSBRUCK, Austria, Dec. 11, 2024 /PRNewswire/ --…
AV-Comparatives Announces Outstanding Results of Cybersecurity Solutions in 2024 Endpoint Prevention and Response (EPR) Test
Download the full report here. INNSBRUCK, Austria, Dec. 11, 2024 /PRNewswire/ --…
AV-Comparatives Announces Outstanding Results of Cybersecurity Solutions in 2024 Endpoint Prevention and Response (EPR) Test
Download the full report here. INNSBRUCK, Austria, Dec. 11, 2024 /PRNewswire/ --…
AV-Comparatives Announces Outstanding Results of Cybersecurity Solutions in 2024 Endpoint Prevention and Response (EPR) Test
Download the full report here. INNSBRUCK, Austria, Dec. 11, 2024 /PRNewswire/ --…
Red Cat Holdings to Report Fiscal Second Quarter 2025 Financial Results and Provide Corporate Update on Monday, December 16, 2024
Conference Call to be held Monday, December 16, 2024 at 4:30p.m. Eastern…
WTCH 24 – Countless historical results and a new superpower emerged
BUDAPEST, Hungary, Dec. 8, 2024 /PRNewswire/ -- Every World Teqball Championships is unique…
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
December 08, 2024 12:00 ET | Source: Affimed N.V. The combination of…
Orca Bio Presents Clinical Results on Use of Orca-Q without GvHD Prophylaxis in Patients with Hematological Malignancies at the 66th ASH Annual Meeting
Orca-Q allogeneic T-cell immunotherapy with no GvHD prophylaxis in patients with matched…
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated…
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
— Phase 3 POD1UM-304 trial met primary endpoint of overall survival (OS)…